The Food and Drug Administration (FDA) has discovered that a chemical impurity known as NDMA has been found in certain lots of Zantac (Ranitidine).  NDMA is considered a probable human carcinogen.  The substance was also discovered in various blood pressure medications a year ago which prompted the FDA to recommend recalls of these medications. The FDA is not calling for a recall of Zantac (Ranitidine) at this time. However, Novartis, one of the larger makers of Zantac (Ranitidine), has stopped distribution of the medication.

As more information is gathered on this issue, more specific recommendations can be made. However, at this time, for anyone taking Zantac (Ranitidine), it is reasonable to consider switching to Pepcid (famotidine).  This is a similar medicine which is not implicated with this safety concern.

Please feel free to call the office if you have any questions or concerns.